$GIFT

Giftify’s CardCash Deploys AI-Powered Customer Service Tools to Cut Response Times by More Than 90%

Giftify, Inc. (NASDAQ: GIFT) announced that its subsidiary CardCash reduced customer service response times by over 90% using AI tools and operational changes, without increasing staffing costs. The improvements include AI-assisted information gathering and staff reallocation. CEO Ketan Thakker highlighted the company's focus on AI and operational efficiency to create long-term shareholder value.

Original reporting
Published Oct 1, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$GIFT
Bullish
medium confidence
Mentioned
$GIFT
Relevance
4/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$GIFTBullishLow
01

Why it matters

The announcement highlights a strategic focus on AI to reduce operating expenses, which could modestly improve profitability.

02

Market read

While the AI rollout is a positive operational development, its immediate market impact is expected to be modest.

03

What to watch

Potential need for ongoing AI model maintenance and data privacy considerations

Relevance 4/10Novelty 4/10Timing: today

Background

Giftify operates CardCash, a secondary gift‑card exchange platform, and announced internal AI tools to speed up customer support.

Company-level read

Ticker impact

$GIFTBullishMedium confidence
Context

Giftify announced AI-powered tools cut CardCash support response times >90% without adding staff.

Expected impact

likely modest upside as cost savings are priced in

Evidence & confidence

AI rollout is a cost‑reduction measure; impact depends on scalability and market perception.

Market effects

demonstrates AI adoption in consumer services, may spur peers to consider similar upgrades

U.S. tech services sector sees incremental positive sentiment

limited to AI efficiency narrative, no broad macro effect

Counterpoint

Cost savings may be offset by implementation risks and limited revenue upside

Key entities

  • Giftify, Inc.

    Parent company of CardCash, listed on NASDAQ as GIFT

  • Abe Nojowitz

    Vice President of Operations at CardCash, led the AI initiative

Related articles

$NVDAMedAI 8/10

NVIDIA’s Next Supply Chain Supercycle: 2.5x Substrate Capacity, 15x Optical Engines, and the Race to Build AI Factories

NVIDIA announced plans to expand semiconductor manufacturing capacity at GTC Berlin 2026, targeting 2.5x substrate capacity growth and 15x optical engine production by 2027-2028. The company is investing $1.1B in KYEC for U.S. testing expansion, signaling a shift in AI infrastructure focus from chip design to large-scale production.

$LLYMedAI 8/10

Sino-US firms team up to advance drug research

METiS TechBio (HK-listed) and Eli Lilly (NYSE: LLY) partnered to develop AI-powered drug delivery tech, focusing on lipid nanoparticles. METiS could receive up to $1.1B in milestone payments and royalties. Lilly previously partnered with Insilico Medicine (HK-listed) for AI drug discovery, with a deal worth up to $2.75B.

$BBLow

BlackBerry QNX Expands Beyond Automotive Into Robotics, Defense < IT·Gaming < 기사본문

BlackBerry QNX, a division of BlackBerry Ltd., is expanding into autonomous mobile robot (AMR) and defense embedded systems markets, leveraging its expertise in automotive real-time operating systems (RTOS). The company aims to enter these sectors through partnerships, emphasizing safety technologies and virtual development. QNX reported fiscal 2026 revenue of $268 million, up 14% year-over-year. Major customers include BMW, Mercedes-Benz, and Hyundai Mobis.

$MRNAMedAI 8/10

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%

Moderna and Merck's personalized cancer vaccine, intismeran, reduced melanoma recurrence by 42% in a Phase 3 trial. The vaccine, combined with Keytruda, trains the immune system to target tumor proteins. The study involved 1,130 patients, with results replicating earlier Phase 2 data. The effect was noted after six months, suggesting the immune system needs time to activate.